BOSTON--(BUSINESS WIRE)--Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, today announces that through its newly formed subsidiary, ABLS Capital, it has secured investment commitments of $80 million to fund up to ten potential lead optimization programs of promising drug development opportunities that have successfully completed an initial candidate feasibility program. Pursuant to the terms of the ABLS partnership formed between Alli
For more information, please visit
http://www.businesswire.com/news/home/20[...]itments-80-million-Development